直接抑制RAS揭示由RAS G12和Q61突变驱动的致癌信号特征
该研究利用RAS抑制剂直接探究特定RAS突变在癌细胞中的作用,发现RASG12X突变肿瘤中突变RAS可被受体酪氨酸激酶(RTK)激活且PI3K活化依赖突变RAS,而RASQ61X突变不依赖RTK激活MAPK级联。联合抑制RAS和RTK可选择性地抑制RASG12X突变肿瘤生长,并为结直肠癌中RASQ61X突变作为EGFR抑制继发耐药机制提供解释。
要点
- RASG12X突变肿瘤中突变RAS可被RTK激活,PI3K活化依赖突变RAS。
- RASQ61X突变不依赖RTK激活MAPK,抑制RASQ61X不影响PI3K通路。
- 联合抑制RAS和RTK选择性抑制RASG12X突变肿瘤生长,与RAS亚型及肿瘤类型无关。
核心结论
- G12X和Q61X突变具有不同致癌信号特征,联合抑制RAS和RTK可选择性抑制RASG12X突变肿瘤生长。
- 研究结果为RASQ61X突变作为结直肠癌EGFR抑制继发耐药机制提供了机制解释。
研究设计与样本
- 本研究在癌细胞中直接利用RAS抑制剂探究特定RAS突变的作用,涵盖体外和体内实验。
主要发现
- 在RASG12X突变肿瘤中,突变RAS可被受体酪氨酸激酶(RTK)激活,且PI3K激活依赖突变RAS。
- RASQ61X突变不依赖RTK激活MAPK级联,抑制RASQ61X可损害MAPK通路激活但不影响PI3K通路。
- 联合抑制RAS和RTK可选择性地抑制RASG12X突变肿瘤的生长,无论RAS亚型和肿瘤类型如何,体外和体内均如此。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: RAS genes are frequently mutated in cancer, often at codons 12 and 61. With the recent introduction of RAS inhibitors, we can now directly investigate the effects of specific RAS mutations in cancer cells. In this study, we demonstrate that in tumors with RASG12X mutations, mutant RAS can be activated by receptor tyrosine kinases (RTK), and PI3K activation is dependent on mutant RAS. Conversely, RASQ61X mutations activate the MAPK cascade independently of RTKs, and inhibition of RASQ61X impairs MAPK pathway activation but leaves the PI3K pathway unaffected. Our characterization of these distinct features of G12X and Q61X mutations suggests that co-inhibition of RAS and RTKs selectively inhibits the growth of RASG12X-mutant tumors, both in vitro and in vivo, regardless of the RAS isoform and tumor type. Additionally, our findings offer a mechanistic explanation for the increased frequency of RASQ61X mutations as a secondary resistance mechanism against EGFR inhibition in colorectal cancer. SIGNIFICANCE: RAS inhibition in multiple tumor types reveals the difference between G12 mutants and Q61 mutants in their cooperation with upstream regulators and downstream effectors to promote oncogenic signaling. Our findings provide the rationale for combinatorial approaches and contribute to explaining the nonuniform distribution of RAS mutations, de novo and at resistance.
引用
- Marasco M, Kumar D, Garcia Borrego S, et al. Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. Cancer Discov. 2025. PMID: 40294008. doi:10.1158/2159-8290.CD-24-0614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。